Welcome to our dedicated page for 0913693 B.C. Ltd. news (Ticker: REPCF), a resource for investors and traders seeking the latest updates and insights on 0913693 B.C. Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 0913693 B.C. Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 0913693 B.C. Ltd.'s position in the market.
RepliCel Life Sciences announced the appointment of Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, as their clinical advisor for the skin rejuvenation product RCS-01 in Japan. Collaborating with CJ Partners and Accerise, the company prepares for a next-phase clinical study under the Act for Safety of Regenerative Medicine. RCS-01, an autologous cell therapy, has shown promising results in increasing collagen-related biomarkers.
The study indicates potential for reversing aging effects in skin.
RepliCel Life Sciences (OTC PINK:REPCF) has launched the second stage of a collaborative research project with the University of British Columbia. This project, led by Dr. Kevin McElwee and Professor Youwen Zhou, aims to confirm unique cell markers in hair follicle cells, enhancing manufacturing and clinical efficacy for RepliCel's cell therapy products. This follows prior research identifying significant gene and protein expressions to improve cell isolation. The project is expected to result in new patents, enhancing RepliCel's technology and product portfolio.
RepliCel Life Sciences has successfully received grants and allowances for seven patent applications across several countries, enhancing its regenerative medicine technology portfolio. Key achievements include a patent granted in China and three notices of allowance in the United States, Japan, and Israel for its dermal injector technology. Additionally, three patents related to Chronic Achilles Tendinopathy received approval in South Korea and New Zealand. This strategic patent expansion supports its commercialization partnerships in key markets, notably with MainPointe Pharmaceuticals and YOFOTO (China) Health.
RepliCel Life Sciences announces the appointment of Professor Tsukasa Kumai as clinical advisor for tendon regeneration product RCT-01 in Japan. Kumai is a prominent sports medicine expert, part of Japan's Olympic Committee Medical and Scientific Staff. The company plans to advance RCT-01's clinical testing under Japan's Act for Safety of Regenerative Medicine, aiming for commercial launch upon successful trials. RepliCel's innovative cell therapies target chronic tendon degeneration, with previous studies showing promising safety and efficacy.
RepliCel Life Sciences (OTC PINK: REPCF) has successfully concluded the second tranche of an investment agreement with MainPointe Pharmaceuticals, involving the purchase of 1,777,778 common shares for CAD $1.2 million. This is part of a larger commitment totaling CAD $2.7 million for four million shares at CAD $0.675 each. The investment will also cover regulatory costs for launching RepliCel's dermal injector products in the United States. The final tranche is set for August 2021, enhancing RepliCel's financial position and regulatory prospects.
RepliCel Life Sciences Inc. (OTC PINK:REPCF) announced its participation in the RINK Festival in Kanagawa, Japan, where CEO R. Lee Buckler presented the company's technology and commercialization plans. This event aims to foster collaboration in regenerative medicine. RepliCel is actively pursuing clinical testing and commercialization of three innovative therapies in Japan, including skin rejuvenation and tendon regeneration cell therapies. The company has established partnerships for product development and is preparing for regulatory compliance with Japan's health authorities.
RepliCel Life Sciences has announced the successful closure of the first tranche of an investment agreement with MainPointe Pharmaceuticals, totaling CAD $2.7 million. This investment involves the purchase of four million common shares at CAD $0.675 each, with 729,024 shares purchased for CAD $492,091 in the first tranche. The second tranche of CAD $1.2 million is set to close by the end of February 2021. The funding will support RepliCel's cell therapy product pipeline aimed at treating aesthetic and orthopedic conditions.
RepliCel Life Sciences provides an update on its strategic initiatives for 2021, focusing on the commercial launch of its dermal injector and advancing its cell therapy products. The company plans to conduct clinical testing in China and Japan and aims for regulatory approval in the U.S. and Hong Kong. RepliCel's partnerships with MainPointe and YOFOTO support these efforts, with key clinical studies underway. The company anticipates significant progress across multiple programs and markets, citing aims for FDA approval and various clinical trial launches within the next 24 months.